Citations 1
Vasopressin V1a and V1b receptor antagonism does not affect the efficacy of tolvaptan in polycystic kidney disease
Nanayakkara, K.D.L. , Hu, Jinghua , Nanayakkara, Kavini , Hu, Jinghua , Torres, Vicente E , Wang, Xiaofang , Li, Jiang , Torres, Vicente E.
American Journal of Physiology-Renal Physiology | May 26, 2025 | Volume: 329 | Issue: 1 | Pages: F20-F31
Currently, the vasopressin V2 receptor antagonist tolvaptan is the only approved treatment for autosomal dominant polycystic kidney disease (ADPKD). It has been suggested that vasopressin acting on V1a or V1b receptors may also affect its development. We show that a V1aR antagonist has no effect in an ADPKD mouse model (Pkd1RC/RC), whereas a V2R antagonist has a modest attenuating effect in female mice only. Neither potentiates or hinders the beneficial effect of tolvaptan when administered in combination with this drug.